Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80
Organisation › Details

Royalty Pharma plc (Nasdaq: RPRX)

Founded in 1996, Royalty Pharma is the industry leader in acquiring pharmaceutical royalties. Royalty Pharma funds innovation in life sciences both directly and indirectly: directly when it partners with life sciences companies to co-develop and co-fund products in late-stage clinical trials, and indirectly when it acquires existing royalty interests from the original innovators (academic institutions, research hospitals, foundations and inventors). The company’s portfolio includes royalty interests in over 45 approved products including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta. Royalty Pharma is also a leading investor in pre-approval royalties, having since 2011 invested over $5.6 billion in royalties on pre-approval products and committed over $1.2 billion to direct R&D funding in exchange for royalties. *

 

Period Start 2020-06-17 existent
Products Industry IP services
  Industry 2 pharmaceutical
Person Person Legorreta, Pablo (Royalty Pharma 202006 CEO + Founder)
     
Region Region New York, NY
  Country United States (USA)
  City n. a. 
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
  Currency USD
  Annual sales 500,879,000 (income, total, consolidated (2019/20) 2020-03-31)
  Profit 109,096,000 (2020-03-31)
  Cash 624,367,000 (2020-03-31)
     
    * Document for �About Section�: AiCuris Anti-infective Cures GmbH. (6/9/20). "Press Release: Royalty Pharma Acquires Partial Royalty Interest on Prevymis (Letermovir) from AiCuris Anti-infective Cures GmbH". New York, NY & Wuppertal.
     
   
Record changed: 2021-06-05

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Royalty Pharma plc (Nasdaq: RPRX)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px




» top